Kiniksa Pharmaceuticals International, plc (KNSA)
$95.02-3.74-3.79%Nov 10
Loading chart…
USA›Health Care›Biotechnology›Biotechnology
M.Cap$7.5B
Dividends—
Next report—
Forecast
Target
P/E68.5
P/S7.48
P/B10.51
5-y avg sales growth+0.0%
Debt / EBITDA0.11
ROE10.4%
Altman Z-score10.35 (safe)
RSI62
MFI61
Price / MA50+17.3% (high) ↓
Trend pattern
Financial Statements
No data available
Team
Loading…
Leadership Changes
Sign in to view leadership changes
Sign in
No changes found
Insider Activity
Loading…
DateTypeDescription
Loading…
Earnings Transcripts
Loading…
Dividends
Loading…
Investor Presentations
Loading…
Options
Expiration from:
to:
Strike from:
to:
Loading options…
Loading bonds…
Stress Test
Loading…
About

Kiniksa Pharmaceuticals is a biopharmaceutical company that seeks to develop and market therapeutic medicines for patients who suffer from severe, unmet medical conditions globally. The company has several product candidates in its pipeline, including ARCALYST, Mavrilimumab, Vixarelimab, and KPL-404, which are in different clinical trial phases. The company was founded in 2015 and is headquartered in Hamilton, Bermuda.

https://www.kiniksa.com
Beta 0.10